Interleukin-6 (IL-6)
IL-6 is the archetypal pleiotropic cytokine — a single molecule that bridges innate and adaptive immunity, orchestrates the acute-phase response, drives haematopoiesis, and (when dysregulated) fuels the most dangerous cytokine-driven pathologies of our era. Its structural 4-helix bundle fold is shared with IL-11, IL-31, OSM, LIF, and CNTF. Signal transduction requires a unique dual-receptor architecture: the ligand-binding IL-6R (CD126) paired with the signal-transducing gp130 (CD130). The distinction between classical signalling (membrane IL-6R) and trans-signalling (soluble IL-6R) elegantly explains why IL-6 can simultaneously be essential for host defence and pathological when overproduced.
Signalling Pathway
Classical vs. Trans-Signalling
CLASSICAL SIGNALLING TRANS-SIGNALLING
(membrane-bound IL-6R, restricted (soluble IL-6R, ubiquitous)
expression: hepatocytes, some
leukocytes)
│ │
IL-6 binds membrane IL-6R (CD126) IL-6 binds sIL-6R (shed by ADAM10/17)
│ │
└──────── IL-6 / IL-6R complex ───────────────┘
│
│ Binds gp130 homodimer (ubiquitously expressed)
│
▼
[gp130]═══[gp130] (hexameric complex: 2×IL-6 + 2×IL-6R + 2×gp130)
│
│ JAK1 and JAK2 constitutively associated with gp130
│ Trans-phosphorylation of JAKs → activated
│
▼
JAK1/2 active
│
┌────────┴────────┐
▼ ▼
STAT3 SHP2/RAS/ERK
phosphorylated pathway
(Y705, S727) │
│ ▼
Dimerisation MAPK cascade
Nuclear (proliferation,
translocation survival)
│
▼
STAT3 target genes:
SOCS1/3 (negative feedback)
BCL2, MCL1 (survival)
Acute-phase proteins (hepatocytes)
MHC class I, IL-17, IL-22 induction
Why trans-signalling matters therapeutically: Classical signalling is largely beneficial — it is required for hepatocyte acute-phase protein production and mucosal defence. Trans-signalling via sIL-6R allows IL-6 to act on virtually any nucleated cell (all express gp130), amplifying inflammatory effects in sites that do not normally express membrane IL-6R. Sgp130Fc (olamkicept) can selectively block trans-signalling while preserving classical signalling — a therapeutic distinction relevant to IBD.
Acute-Phase Response
IL-6 is the principal inducer of the hepatic acute-phase response — a systemic inflammatory programme that redirects liver protein synthesis within hours of infection or tissue injury. This shifts hepatocyte output from constitutive proteins (negative acute-phase reactants) to protective acute-phase proteins (positive reactants).
Positive Acute-Phase Proteins (induced)
- CRP (C-reactive protein) — opsonin, complement activator; rises 1,000-fold; gold standard inflammatory marker
- Fibrinogen — coagulation factor I; elevated in inflammation → ↑ESR
- SAA (serum amyloid A) — apolipoprotein; opsonin; HDL-associated; chronic elevation → AA amyloidosis
- Ferritin — iron-storage; ↑ sequesters iron from pathogens; marker of hyperferritinaemic syndromes (MAS, sHLH)
- Hepcidin — key iron regulator; IL-6-induced → ↓ferroportin → ↓serum iron → anaemia of chronic disease
- Complement components (C3, C4, factor B) — enhanced innate opsonisation
- Haptoglobin, α1-antitrypsin, fibronectin
Negative Acute-Phase Proteins (suppressed)
- Albumin — constitutive plasma protein; falls during inflammation; low albumin = severity marker in sepsis, malnutrition
- Transferrin — iron-transport protein; decreased → contributes to iron sequestration
- Transthyretin (prealbumin) — short half-life; sensitive marker of nutritional status and acute illness
- Retinol-binding protein
- α2-macroglobulin (humans; positive in rodents)
Anaemia of chronic disease: IL-6-driven hepcidin production is the molecular explanation for why patients with RA, cancer, and chronic infection develop a normocytic, normochromic anaemia refractory to iron supplementation — iron is trapped inside macrophages and enterocytes by ferroportin degradation. Tocilizumab treatment measurably reduces hepcidin and improves haemoglobin in RA.
Therapeutic Targeting
| Drug | Class | Target | Route | Approved Indications |
|---|---|---|---|---|
| Tocilizumab (Actemra) | Humanised monoclonal antibody | IL-6R (blocks both mIL-6R and sIL-6R) | IV / SC | RA, polyarticular/systemic JIA, giant-cell arteritis (GCA), cytokine release syndrome (CAR-T, tisagenlecleucel), COVID-19 severe pneumonia (hospitalised, on O₂) |
| Sarilumab (Kevzara) | Human monoclonal antibody | IL-6R (blocks both mIL-6R and sIL-6R) | SC | RA (moderate-to-severe, MTX-inadequate response or intolerant) |
| Siltuximab (Sylvant) | Chimeric monoclonal antibody | IL-6 (ligand itself) | IV | Multicentric Castleman disease (MCD) without HIV/HHV-8; occasionally used off-label in cytokine storms |
| Baricitinib (Olumiant) | JAK1/JAK2 inhibitor (small molecule) | JAK1, JAK2 (downstream of gp130, IL-6R, and multiple other cytokine receptors) | Oral | RA, alopecia areata, COVID-19 (hospitalised requiring O₂), atopic dermatitis |
| Tofacitinib (Xeljanz) | JAK1/JAK3 inhibitor (small molecule) | JAK1, JAK3 (and JAK2 at higher doses) | Oral | RA, psoriatic arthritis, UC, polyarticular JIA; now with black-box warning re: cardiovascular risk (ORAL Surveillance study) |
| Upadacitinib (Rinvoq) | Selective JAK1 inhibitor | JAK1 (preferred selectivity) | Oral | RA, PsA, AS, nr-axSpA, atopic dermatitis, UC, Crohn's disease |
Anti-IL-6R vs. anti-IL-6 vs. JAK inhibitors: Anti-IL-6R antibodies (tocilizumab, sarilumab) block the receptor and cause accumulation of free IL-6 in plasma — a useful biomarker for drug activity but can cause IL-6 rebound on dose interruption. Anti-IL-6 antibodies (siltuximab) directly neutralise the cytokine. JAK inhibitors act downstream, blocking multiple cytokine pathways simultaneously — broader immunosuppression but also broader side-effect profile (opportunistic infections, VTE, lipid changes). JAK inhibitor selectivity (JAK1 vs. JAK2 vs. JAK3) affects which cytokine pathways are preferentially blocked and the safety/efficacy trade-offs.
Pathology
| Condition | IL-6 Role | Key Features | Treatment implications |
|---|---|---|---|
| Cytokine storm / CRS (COVID-19, CAR-T therapy) | IL-6 is the dominant driver; massively elevated serum IL-6 correlates with severity and ICU admission | Fever, hypoxia, bilateral infiltrates, organ dysfunction; CAR-T CRS: fever, hypotension, neurotoxicity (ICANS) | Tocilizumab dramatically reduces need for mechanical ventilation and 28-day mortality in COVID-19 (RECOVERY trial); first-line for CAR-T CRS grade ≥2 |
| Rheumatoid arthritis | IL-6 produced by synoviocytes drives pannus formation, osteoclast activation, and systemic features | Symmetric polyarthritis, morning stiffness, elevated CRP/ESR, erosive disease | Tocilizumab/sarilumab effective as monotherapy (unlike most biologics that require MTX background); normalise CRP rapidly |
| Giant-cell arteritis (GCA) | IL-6 drives granulomatous vasculitis of large vessels; elevated in virtually all active GCA | Temporal headache, jaw claudication, vision loss risk (anterior ischaemic optic neuropathy) | Tocilizumab SC weekly is FDA-approved; reduces relapse rate and cumulative steroid dose (GiACTA trial) |
| Multiple myeloma | IL-6 acts as a growth and survival factor for malignant plasma cells; drives resistance to apoptosis via STAT3/BCL2 | Bone lesions, hypercalcaemia, renal impairment, anaemia, M-protein | IL-6 blockade has been explored; current therapy includes proteasome inhibitors (bortezomib), IMiDs, anti-CD38 (daratumumab) |
| Castleman disease (MCD) | HHV-8-negative MCD driven by IL-6 hypersecretion; IL-6 is the cardinal disease mediator | Lymphadenopathy, constitutional symptoms, hepatosplenomegaly, anaemia, CRP markedly elevated | Siltuximab (anti-IL-6) approved; tocilizumab used off-label; rituximab for HHV-8+ variant |
| Colorectal cancer | Tumour-promoting: IL-6/STAT3 drives epithelial survival, angiogenesis, and immunosuppression in TME | Elevated serum IL-6 correlates with metastatic burden and worse prognosis | Research: IL-6 pathway inhibition being explored as adjunct to checkpoint immunotherapy; no approved IL-6-targeted regimen yet |
Connections
References
- Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448-57. doi:10.1038/ni.3153 · PubMed 25898198
- Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47. doi:10.7150/ijbs.4989 · PubMed 23136552
- RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY). Lancet. 2021;397(10285):1637-45. doi:10.1016/S0140-6736(21)00676-0 · PubMed 33933206
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis (GiACTA). N Engl J Med. 2017;377(4):317-28. doi:10.1056/NEJMoa1703093 · PubMed 28745999
- Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi:10.1101/cshperspect.a016295 · PubMed 25190079